These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32809976)

  • 1. Urinary biomarkers of mycobacterial load and treatment response in pulmonary tuberculosis.
    Xia Q; Lee MH; Walsh KF; McAulay K; Bean JM; Fitzgerald DW; Dupnik KM; Johnson WD; Pape JW; Rhee KY; Isa F
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32809976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass Spectrometric Identification of Urinary Biomarkers of Pulmonary Tuberculosis.
    Isa F; Collins S; Lee MH; Decome D; Dorvil N; Joseph P; Smith L; Salerno S; Wells MT; Fischer S; Bean JM; Pape JW; Johnson WD; Fitzgerald DW; Rhee KY
    EBioMedicine; 2018 May; 31():157-165. PubMed ID: 29752217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentially Detectable Mycobacterium tuberculosis Cells in Sputum from Treatment-Naive Subjects in Haiti and Their Proportionate Increase after Initiation of Treatment.
    McAulay K; Saito K; Warrier T; Walsh KF; Mathurin LD; Royal-Mardi G; Lee MH; Ocheretina O; Pape JW; Fitzgerald DW; Nathan CF
    mBio; 2018 Nov; 9(6):. PubMed ID: 30459198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts.
    Kawasaki M; Echiverri C; Raymond L; Cadena E; Reside E; Gler MT; Oda T; Ito R; Higashiyama R; Katsuragi K; Liu Y
    PLoS Med; 2019 Apr; 16(4):e1002780. PubMed ID: 30978194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure.
    Ambreen A; Jamil M; Rahman MAU; Mustafa T
    BMC Infect Dis; 2019 Oct; 19(1):923. PubMed ID: 31666021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial.
    Manyazewal T; Woldeamanuel Y; Holland DP; Fekadu A; Blumberg HM; Marconi VC
    Trials; 2020 May; 21(1):383. PubMed ID: 32370774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response.
    Adekambi T; Ibegbu CC; Cagle S; Kalokhe AS; Wang YF; Hu Y; Day CL; Ray SM; Rengarajan J
    J Clin Invest; 2015 May; 125(5):1827-38. PubMed ID: 25822019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring therapeutic efficacy by real-time detection of Mycobacterium tuberculosis mRNA in sputum.
    Mdivani N; Li H; Akhalaia M; Gegia M; Goginashvili L; Kernodle DS; Khechinashvili G; Tang YW
    Clin Chem; 2009 Sep; 55(9):1694-700. PubMed ID: 19574468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis.
    Thai PVK; Ha DTM; Hanh NT; Day J; Dunstan S; Nhu NTQ; Kiet VS; Lan NH; Dung NH; Lan NTN; Thuong NT; Lan NN; Liễu PTT; Hồng NT; Điệp ĐC; Thanh NTK; Hội NV; Nghĩa NV; Đại TN; Minh HQ; Thơm NV; Farrar J; Caws M
    BMC Infect Dis; 2018 Mar; 18(1):112. PubMed ID: 29510687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of Mycobacterium tuberculosis-specific IFN-γ responses and sputum bacillary clearance in HIV-infected adults during treatment of pulmonary tuberculosis.
    Mzinza DT; Sloan DJ; Jambo KC; Shani D; Kamdolozi M; Wilkinson KA; Wilkinson RJ; Davies GR; Heyderman RS; Mwandumba HC
    Tuberculosis (Edinb); 2015 Jul; 95(4):463-9. PubMed ID: 26051653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urine lipoarabinomannan to monitor antituberculosis therapy response and predict mortality in an HIV-endemic region: a prospective cohort study.
    Drain PK; Gounder L; Grobler A; Sahid F; Bassett IV; Moosa MY
    BMJ Open; 2015 Apr; 5(4):e006833. PubMed ID: 25877271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model-Based Relationship between the Molecular Bacterial Load Assay and Time to Positivity in Liquid Culture.
    Svensson RJ; Sabiiti W; Kibiki GS; Ntinginya NE; Bhatt N; Davies G; Gillespie SH; Simonsson USH
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood transcriptomic markers of
    Dupnik KM; Bean JM; Lee MH; Jean Juste MA; Skrabanek L; Rivera V; Vorkas CK; Pape JW; Fitzgerald DW; Glickman M
    Int J Tuberc Lung Dis; 2018 Aug; 22(8):950-958. PubMed ID: 29991407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing rates of mycobacterial clearance in sputum smear-negative and smear-positive adults living with HIV.
    Machowski EE; Letutu M; Lebina L; Waja Z; Msandiwa R; Milovanovic M; Gordhan BG; Otwombe K; Friedrich SO; Chaisson R; Diacon AH; Kana B; Martinson N
    BMC Infect Dis; 2021 May; 21(1):466. PubMed ID: 34022850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
    Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M
    Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar.
    Al-Shaer MH; Elewa H; Alkabab Y; Nazer LH; Heysell SK
    BMC Infect Dis; 2018 Aug; 18(1):384. PubMed ID: 30089476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome.
    Holtz TH; Sternberg M; Kammerer S; Laserson KF; Riekstina V; Zarovska E; Skripconoka V; Wells CD; Leimane V
    Ann Intern Med; 2006 May; 144(9):650-9. PubMed ID: 16670134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.